Home › Steatotic Liver Disease › Virginia › Richmond
Steatotic Liver Disease clinical trials in Richmond, VA
12 studies for Steatotic Liver Disease are looking for participants at sites in and around Richmond (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RecruitingPhase 2
- Virginia Commonwealth University, Richmond
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
RecruitingPhase 2
- Richmond Veterans Administration Medical Center, Richmond
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
RecruitingPhase 3
- Richmond Veterans Affairs Medical Center (Richmond VA Medical Center), Richmond
- Virginia Commonwealth University (VCU) Medical Center, Richmond
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RecruitingPhase 3
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- and 1 more
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 2
- GI Alliance Richmond, Richmond
- GI Select Health Research, Richmond
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
RecruitingPhase 2
- GSK Investigational Site, Richmond
- GSK Investigational Site, Richmond
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
RecruitingPhase 2
- GSK Investigational Site, Richmond
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
RecruitingPhase 2
- Virginia Commonwealth University, Richmond
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Recruiting
- Virginia Common wealth University, Richmond
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
RecruitingObservational study
- Virginia Commonwealth University, Richmond
About Steatotic Liver Disease
Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Learn about the causes and treatments.
More about Steatotic Liver Disease on MedlinePlus
Steatotic Liver Disease trials in other cities
- San Antonio, TX17 studies
- Miami, FL16 studies
- New York City, NY16 studies
- San Diego, CA14 studies
- Houston, TX13 studies
- Austin, TX13 studies
- Chandler, AZ10 studies
- Tucson, AZ10 studies
- St. Louis, MO9 studies
- Hialeah, FL9 studies
- Dallas, TX9 studies
- Orlando, FL9 studies
Other studies in Richmond
- Breast Cancer26 studies
- Non-Small Cell Lung Cancer25 studies
- Prostate Cancer19 studies
- Heart Failure16 studies
- Lung Cancer14 studies
- Cardiovascular Disease13 studies
- Colorectal Cancer13 studies
- Acute Myeloid Leukemia12 studies
- Metastatic Cancer12 studies
- Head and Neck Squamous Cell Carcinoma12 studies
- Melanoma11 studies
- Obesity11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.